Stockreport

Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

Nuvectis Pharma, Inc.  (NVCT) 
PDF NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S. FDA. Updated Phase 1b re [Read more]